MarketPulse

pharmaceutical pipeline

11 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Can Eli Lilly Become First $2T Healthcare Giant? Three Growth Catalysts in Focus

Eli Lilly eyes $2 trillion valuation from weight-loss drugs, Alzheimer's breakthroughs, and AI-powered R&D following recent market pullback.
PFENVDALLYREGNhealthcare stocksweight loss drugs
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

PARP Inhibitor Pipeline Surges: 25+ Pharma Giants Race to Expand Cancer Drug Arsenal

Over 25 pharma companies develop 30+ PARP inhibitors in trials, with AstraZeneca and Gilead leading expansion into multiple cancer indications including glioblastoma and prostate cancer.
AZNGILDALLRclinical trialscancer treatment
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Morgan Stanley Sees 52% Upside for Eli Lilly as Weight-Loss Drugs Reshape Revenue

Morgan Stanley analyst targets $1,327 for Eli Lilly, citing $45B weight-loss drug sales potential by 2030, implying 52% upside from current $870 levels.
LLYCVSNVOweight loss drugsZepbound
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

US Eosinophilic Esophagitis Market Poised for Explosive Growth as Novel Drug Classes Emerge

US eosinophilic esophagitis market valued at $647M in 2025 projected to grow 13.2% annually through 2036, driven by novel drug classes and improved diagnostics.
AMGNSNYAZNREGNEPRX+3market growthpharmaceutical pipeline
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Idiopathic Membranous Nephropathy Market Poised to Hit $1B by 2036

IMN market expected to grow nearly 8x from $130M in 2025 to $1B by 2036, driven by novel therapies addressing unmet treatment needs.
NKTXVRTXRHHBYAZNBIIB+2clinical trialspharmaceutical pipeline
The Motley FoolThe Motley Fool··Adria Cimino

Pfizer at a Crossroads: Patent Cliffs and Pipeline Bets Define Next Chapter

Pfizer faces patent cliffs and COVID vaccine decline, betting on oncology and obesity drug pipelines to drive future growth amid acquisition integration challenges.
PFELLYNVOclinical trialsacquisitions
BenzingaBenzinga··Vandana Singh

Eli Lilly Poised to Challenge AstraZeneca in Abivax Bidding War

AstraZeneca has exclusive access to Abivax data until March 23. If it misses deadline, Eli Lilly could rejoin bidding for French biotech valued by 1,600% surge.
LLYAZNABVXacquisitionbiotech
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Pfizer and Novo Nordisk: Undervalued Pharma Giants Poised for Rebounds

Pfizer and Novo Nordisk trade at 9x-10.5x forward earnings with deep pipelines offering long-term value potential despite recent underperformance.
PFELLYNVOclinical trialshealthcare stocks
BenzingaBenzinga··Prnewswire

Orexo Restructures Leadership to Pivot Toward Drug Development After Zubsolv Sale

Orexo restructures leadership and divests Zubsolv to focus on drug development and AmorphOX technology advancement.
ORXOYproduct developmentorganizational restructuring
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Acute Ischemic Stroke Market Set for Double-Digit Growth as Novel Therapies Advance

Acute ischemic stroke market poised for significant growth through 2036, driven by novel therapies including recently approved tenecteplase and promising pipeline candidates addressing 1.8 million annual cases.
BMYCELGrAZNDMACclinical trialsmarket growth
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly Strengthens Market Position With Weight-Loss Drug Success

Eli Lilly strengthens market position with blockbuster weight-loss drug Zepbound, diversified pipeline, and AI integration, supporting consistent financial performance and shareholder returns.
LLYdividend growthweight loss drugs